VICTORY
A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression After Coronary Bypass Surgery in Diabetic Patients
Sponsor study identifier
Secondary identifiers
interventional
193
2 countries
9
Study Start
June 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2007
Actual (reported)Study Completion
July 2007
Actual (reported)HYPOTHESES
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2003
Date type not reportedThis date has not been verified as actual or estimated.
September 12, 2005
Actual (reported)September 15, 2005
Actual (reported)July 2007
Actual (reported)July 2007
Actual (reported)Change in plaque volume in one SVG (by IVUS)
12 months
1 Change in plaque volume in segment of anastomosed coronary artery
12 months
2 Changes in lumen and total vessel volumes and lumen plaque total vessel areas in SVG and coronary segments
12 months
3 Changes in qualitative plaque characterization in the SVG and coronary segments
12 months
4 Patients showing atherosclerosis changes
12 months
5 Atherosclerosis changes concordance and discordance
12 months
Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
QEII Health Sciences Center - Halifax Infirmary
Halifax, Nova Scotia, B3H 3A7, Canada
Hamilton Health Sciences - Mc Master Clinic
Hamilton, Ontario, L8L 2X2, Canada
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
CRMSBC
Bonaventure, Quebec, G0C 1E0, Canada
CHUM Notre-Dame Hospital
Montreal, Quebec, H2L 4M1, Canada
Laval Hospital
Sainte-Foy, Quebec, G1V 4G5, Canada
Hospital Del Mar
Barcelona, Spain
Bertrand OF, Poirier P, Rodes-Cabau J, Rinfret S, Title LM, Dzavik V, Natarajan M, Angel J, Batalla N, Almeras N, Costerousse O, De Larochelliere R, Roy L, Despres JP; VICTORY Trial Investigators. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis. 2010 Aug;211(2):565-73. doi: 10.1016/j.atherosclerosis.2010.06.005. Epub 2010 Jun 11.
Olivier F Bertrand, MD, PhD
Laval Hospital Research Center
Jean-Pierre Despres, PhD
Laval Hospital Research Center
Paul Poirier, MD, PhD
Laval Hospital Research Center
193 participants (actual enrollment reported by the registry).
First Submitted
September 12, 2005
First Posted
September 15, 2005
Study Start
June 2003
Date type not reportedThis date has not been verified as actual or estimated.
Diabetes Health Enhancement Program to Improve Health of People With Diabetes
Contact the study team to confirm eligibility.
Hospital Universitari Vall D'Hebron
Barcelona, Spain
Hospital Universitarion Son Dureta
Palma de Mallorca, Spain
Primary Completion
July 2007
Actual (reported)Study Completion
July 2007
Actual (reported)Last Updated
October 10, 2008
Record last verified: 2008-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: